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Abstract
Introduction: In Brazil, the use of antiretrovirals is widespread: more than 260,000 individuals are currently undergoing
treatment. We conducted a survey targeting antiretroviral-naı¨ve individuals who were initiating antiretroviral therapy (ART)
according to local guidelines. This survey covered five Brazilian regions.
Methods: The HIV Threshold Survey methodology (HIV-THS) of the World Health Organization was utilized, and subjects were
selected from seven highly populated cities representative of all Brazilian macro-regions. Dried blood spots (DBS) were collected
on SS903 collection cards and were transported by regular mail at room temperature to a single central laboratory for
genotyping.
Results: We analysed samples from 329 individuals initiating highly active antiretroviral therapy (HAART), 39 (11.8%) of whom
were harbouring transmitted drug resistance (TDR). The mean CD4 T cell count was 253 cells/mL, and the mean viral load was
142,044 copies/mL. The regional prevalence of resistance was 17.0% in the Northeast, 12.8% in the Southeast, 10.6% in the
Central region, 8.5% in the North and 8.5% in the South. The inhibitor-specific TDR prevalence was 6.9% for nucleoside reverse
transcriptase inhibitors, 4.9% for non-nucleoside reverse transcriptase inhibitors and 3.9% for protease inhibitors; 3.6% of
individuals presented resistance to more than one class of inhibitors. Overall, there were trends towards higher prevalences of
subtype C towards the South and subtype F towards the North. Of the DBS samples collected, 9.3% failed to provide reliable
results.
Discussion: We identified variable TDR prevalence, ranging from intermediate to high levels, among individuals in whom HIV
disease progressed, thus implying that resistance testing before initiating ART could be effective in Brazil. Our results also
indicate that the use of DBS might be especially valuable for providing access to testing in resource-limited and remote settings.
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Introduction
As of December 2012, more than 260,000 individuals were
receiving antiretroviral treatment in Brazil, accounting for
almost two-thirds of the individuals living with HIV who are
followed by the Brazilian Public Health System (www.aids.
gov.br). Brazil also provides a network of laboratories offering
monitoring tests. However, according to current local guide-
lines, only patients under virologic antiretroviral failure are
entitled to obtain the genotyping tests, which are performed
in a network of specialized laboratories [1].
From April 2010 to December 2012, Brazilian guidelines
recommended treatment for patients with CD4 Tcell counts
below 350 cells/mL. Therefore, we decided to conduct surveys
in targeted Brazilian macro-regions of antiretroviral-naı¨ve
individuals living with HIV who were initiating antiretroviral
treatment according to the local guidelines. We hypothesized
that individuals initiating treatment would generally have
low CD4 T cell counts, indicating that HIV disease had
progressed, and that those individuals had been infected for
long periods of time (at a time when antiretroviral treatment
was not widely used and transmitted drug resistance, or TDR,
would therefore be rare).
In Brazil, genotype testing is currently offered only to
persons experiencing virologic failure. Nonetheless, TDR has
been shown to be a pressing issue in Brazil [2]. Furthermore, it
is known that multiple subtypes of HIV infection co-circulate in
Brazil [35], and it is not well understood whether TDR varies
among different subtypes. Therefore, we sought to conduct a
TDR survey spanning multiple regions of Brazil.
Many surveys for determining the prevalence of HIV TDR
have been performed among acutely or recently infected
individuals to mitigate the loss of testing sensitivity related to
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the emergence of wild-type strains. However, in contrast
to what is seen in secondary resistance, besides M184V
mutation, the replacement of resistant strains with wild-type
strains is not likely to occur [68], as there is a genetic
bottleneck during primary HIV infection that leads to the
clonal transmission of HIV of a certain genetic profile [9].
Therefore, we believe that even at a time long after the trans-
mission event, genotype testing would be suitably sensitive
for detecting TDR.
Methods
The HIV Threshold Survey methodology (HIV-THS) of the
World Health Organization was utilized in this study. This
method considers a low prevalence of TDR to be less than 5%,
an intermediate prevalence to be between 5 and 15% and a
high prevalence to be levels above 15%. We selected one
highly populated city from each of the five Brazilian macro-
regions and analysed 47 samples from each city: Manaus
(North region), Salvador (Northeast region), Brası´lia (Central
region), Rio de Janeiro (Southeast region) and Porto Alegre
(South region). We also included two additional cities that
have the highest incidences of AIDS and HIV mortality in Brazil
(www.aids.gov.br): Itajaı´ from the South region and Santos
from the Southeast region. The latter was also previously
recognized as having high prevalences of TDR, CRF_28 and
CRF_29 [10,11].
When antiretroviral treatment was prescribed, the attend-
ing physician invited patients to sign informed consent forms
and to provide pre-treatment samples for HIV-1 genotyping
as part of this study. Dried blood spots (DBS) were used in
this study. An attending nurse or physician collected the
samples on SS903 collection cards after a needle puncture of
the finger, and then sent them by regular mail at room
temperature to a single central lab, the Retrovirology Lab of
the Federal University of Sa˜o Paulo, Brazil, for genotyping.
Samples were collected from July 2009 to December 2010.
Genotyping was performed from HIV proviral DNA, which
was extracted using a QIAamp Blood Kit (Qiagen Inc.,
Chatsworth, CA, USA). Protease and reverse transcriptase
(RT) regions of the pol gene were amplified and sequenced as
previously described [11].
TDRwas evaluated according to an algorithm from theWHO
(updated in 2009) that excludes common polymorphisms and
considers 93 mutations: 34 nucleoside reverse transcriptase
inhibitor (NRTI) resistance mutations at 15 RT positions, 19
non-nucleoside reverse transcriptase inhibitor (NNRTI) resis-
tance mutations at 10 RT positions and 40 protease inhibitor
(PI) resistance mutations at 18 protease positions [12].
Phylogenetic analysis was performed for subtype assignment,
in which sequences were aligned to the reference data set
from the Los Alamos database using BioEdit version 7.2.3 [13].
For each alignment, phylogenetic analyses were performed
using the PHYLIP programme package, version 3.57 [14]. The
DNAdist programme was used to calculate distance matrixes
based on the maximum-likelihood model, and neighbour-
joining trees were generated using the Neighbor and Con-
sense programmes. Statistical significance was assessed with
bootstrap tests in a total of 100 replications. Alternatively,
phylogenetic analyses were conducted using MEGA software,
version 5.2.2 [15].
We analysed predictors of TDR including gender, age, risk
factors for HIV acquisition (men who have sex with men,
heterosexual exposure, injectable drug use and transfusion
before the availability of anti-HIV enzyme immunoassay),
reported partner using antiretrovirals and HIV subtype using
chi-square and Fisher’s exact test.
Results
DBS specimens were collected in a total of 352 patients. Of
these, we were able to amplify nucleic acid sequences in 329
patients. Sample collection was then stopped as 329 was
the target number of genotyping tests planned for by the
threshold survey method. The prevalence of non-amplifiable
sequence was similar across all sites (data not shown).
Overall, the prevalence of TDR was 11.6%. This varied by
geographic region (Table 1), ranging from 4.4% in Itajaı´ to
17.0% in Salvador and Santos. Overall, 6.9% of genotypes
showed one or more NRTI mutations, 4.9% had one or more
NNRTI mutations and 3.9% had one or more PI mutations.
Two- or three-class resistance was 3.6% (1.8% to NRTI and
NNRTI, 1.5% to NNRTI and PI and 0.3% to NNRTI and PI).
There was one subject with three-class resistance. Specific
mutations are described in Table 2. There were no relation-
ships between TDR prevalence and gender, HIV subtype or
risk factors for HIV acquisition. Of patients who reported a
sexual partner using antiretrovirals, 11.1% exhibited TDR,
compared to 23% of individuals who did not know the HIV
status of sexual partners (Fisher’s exact test p0.06).
The overall mean and median CD4 T cell counts were
253 and 269 cells/mL, respectively, with a range from 3 to 861
cells/mL. The mean and median CD4 T cell counts among
individuals with TDR were 219 and 250 cells/mL, respectively,
compared to 257 and 271 cells/mL, respectively, among
individuals harbouring wild-type HIV strains, with no sig-
nificant difference between the groups. The overall mean and
median viral loads were 4.68 and 4.70 log10 copies/mL,
respectively, with a range from 2.0 to 6.34 log10 copies/mL.
Again, no significant differences were noted in the mean and
median viral loads between individuals with or without TDR,
which were, respectively, 4.63 and 4.61 log10 copies/mL for
individuals harbouring TDR strains compared to 4.69 and
4.72 log10 copies/mL among individuals harbouring wild-type
strains. Regional differences in the CD4 T cell counts and
viral loads are presented in Table 1.
According to analyses of the protease and RT regions of
the pol gene, a variety of different subtypes and recombinant
forms were detected. Overall, 64.6% of individuals were
infected with pure subtype B, 17.3% with subtype C, 6.0%
with subtype F, 6.8% with BF recombinants, 1.5% with BC
recombinants, 2.7% with CRF31_BC, 0.6% with CRF29_BF,
0.3% with CRF12_BF and 0.3% with subtype D. The regional
prevalences of HIV-1 subtypes are shown in Figure 1.
A phylogenetic analysis using a neighbour-joining phylo-
genetic reconstruction and excluding resistance-related co-
dons revealed no clustering of samples with TDR sequences
when genetic distances B1.5% were used to define clusters
(data on file).
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Discussion
We identified variable prevalences of TDR, from intermediate
(515%) to high (15%), according to geographic region in
individuals with HIV that progressed immediately before
initiation of ART treatment as prescribed by the attending
physician. This report describes a geographically diverse TDR
survey that draws upon multiple areas of Brazil, being truly
representative of all of the various Brazilian macro-regions.
To perform this study, one very populated city was chosen
to represent each Brazilian macro-region. Additionally, two
other cities, Itajaı´ and Santos, were included due to the ex-
plosive nature of their epidemics, which have been char-
acterized by the high incidence of AIDS and the high number
of new HIV cases reported in the last few years (www.aids.
gov.br). Evaluation of in-house genotyping assay using DBS in
the WHO global laboratory network has previously shown
that the reproducibility and accuracy of nucleotide sequence
determination and resistance-associated mutation identifica-
tion from DBS were similar to those previously determined
for plasma [16]. In the current study, genotype results have
been successfully obtained using DBS for regions located far
from a central laboratory able to provide molecular-based
testing, including places such as Manaus, which is located in
the Brazilian rain forest and has high humidity and tempera-
tures. In our study, the distances from the collecting sites to
the central laboratory varied from 74 to 3876 km, with a
mean distance of 2510 km, confirming that DBS can provide
access to molecular-based testing in spite of large distances
and extreme conditions in developing sets. Notably, this
study was designed to detect TDR in a group of individuals in
whom HIV disease had progressed and who, therefore, were
well beyond the HIV transmission event. The overall mean
CD4 T cell count in this group of individuals was 206.5
cells/mL; based on the natural history of HIV progression, it is
estimated that the time to achieve such a CD4 T cell count
is an average of eight years [17]. Despite this length of time,
a considerable prevalence of TDR was detected.
Previous surveys in Brazil that included several different
cities with individuals with recent HIV diagnoses or recent HIV
infections demonstrate that the TDR prevalence is generally
lower than the prevalence in the present study [35,11,1842].
However, we were able to confirm the previously reported
high prevalence of TDR in the city of Salvador, located in
the Northwest region, and Santos in the Southeast region of
Brazil [26].
There is an interesting general trend towards detecting
more TDR mutations to NRTI than to NNRTI in individuals with
longstanding infections, in contrast to individuals with recent
HIV infections [4,43]. The current study indeed confirmed this
trend: the prevalence of resistance was 6.9% to NRTIs and
4.9% to NNRTIs. Twenty-three individuals harboured viruses
with NRTI mutations, 16 individuals harboured viruses with
thymidine analogue mutations (TAMs) and 8 individuals har-
boured viruses with other nucleoside analogue mutations
(NAMs). Ten individuals harboured viruses with a mutation at
RT codon 215, and, as expected from a population harbouring
HIV for a long period of time, 8 individuals were infected with
so-called revertants (215D/C/S/E, Table 1), which are products
of the evolution of T215Y or T215F. Although the revertants
themselves do not present any level of phenotypic resistance
[44], it is plausible that individuals harbouring these rever-
tants have also acquired the T215Yor T215F strains, which are
associated with virologic antiretroviral failure [45]. Of course,
it is theoretically possible that the revertants were trans-
mitted rather than the original T215Y or T215F strains; next-
generation sequencing techniques may be able to answer this
important and interesting question. Furthermore, in accor-
dance with other studies, only three patients in this study
presented mutations in the M184 RT codon. Considering that
the M184V mutation has a much higher prevalence among
individuals with secondary resistance, it is possible that
regular genotyping for determining TDR might underestimate
the prevalence of this mutation. Although TDR mutations
tend to persist over time, M184V might wane more rapidly
[68]. It is also possible that the APOBEC-related hypermuta-
tion plays a role in this process, as valine is encoded by the
codon GTG and methionine is encoded by ATG. Interestingly,
other resistance mutations besides M184V/I that also cause
high fitness cost, such as K65R in one case and D30N in three
cases, have also been detected in this survey. The D30N
mutation is exclusively selected by Nelfinavir among indivi-
duals infected by subtype B viruses, and although this drug
has not been used in Brazil since 2007, it has been extensively
used in Brazil since 1998.
Table 1. Demographic, virologic and immunological characteristics of individuals according to the different Brazilian regions and
TDR prevalence
City/region Mean age (variation) Males (%) Mean CD4 Mean VL log10 TDR (%)
2 classes
resistance (%)
3 classes
resistance (%)
Manaus/N 36 (1861) 59.6 320 (91781) 4.6 (2.45.7) 8.5 2.1
Salvador/NE 38 (1958) 60.9 227 (3581) 5.2 (3.75.9) 17.0 4.3
Brasilia/MW 40 (2163) 77.1 235 (24644) 5.3 (2.06.3) 10.6 4.3
Rio de Janeiro/SE 41 (2776) 89.4 233 (25447) 5.2 (3.55.9) 12.8 4.3
Porto Alegre/S 41 (1865) 63.3 249 (35759) 5.1 (3.05.7) 12.2 2.0
Santos/SE 40 (2669) 65.7 285 (11861) 4.9 (2.75.5) 17.0 3.7 1.9
Itajaı´/S 39 (2563) 65.9 247 (15475) 5.2 (2.46.2) 4.4 2.2
Total 39 (1876) 69.0 253 (3861) 5.2 (2.06.3) 11.6 3.3 0.3
Forty-seven samples have been collected for each site.
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NNRTI resistancemutations were detected in 16 individuals:
9 harboured viruses with the K103M mutation, and three
individuals carried viruses with a mutation at codon 181. Two
NNRTI pathways for resistance may exist, depending on the
drug used. The use of efavirenz primarily selects for the K103N
mutation, which is generally accompanied by the L100I and
P225H mutations, whereas nevirapina predominantly selects
for the Y181C mutation, which is generally accompanied
by the K101E and G190A mutations. The G190A mutation
contributes cross-resistance to the second-generation NNRTI
etravirine [46].
Another important finding of this study is that almost one-
third of individuals harbouring TDR exhibited resistance to two
antiretroviral classes, which has been a rare finding in other
studies. Furthermore, one individual harboured TDR viruses to
three antiretroviral classes. A case-control study performed in
the city of Santos, Brazil, previously showed an association of
multi-antiretroviral class resistance with virology failure, thus
emphasizing the importance of detecting such cases.
This study was able to detect a number of rare HIV sub-
types and recombinants. However, it is clear that subtype B
still prevails in Brazil, with interesting trends towards higher
Table 2. TDR profiles according to the different Brazilian regions and the cities of Santos and Itajaı´
Region or city Sample ID Subtype NRTI NNRTI PI
N MA012_RC B V106A
MA013_RC B D30N, M46I
MA027_RC F M41L, T215E D30N, N88D
MA029_RC B M184V
NE BA001_RC B I54T
BA004_RC B M41L L100I, K103N
BA006_RC B M41L, D67N, L210W, T215D
BA008_RC B M41L, T215CS M46I, L90M
BA012_RC B K219N
BA048_2 B D30N, M46I
BA054 F K103N
BA057 B T215S
MW DF006_RC B T215S
DF012 B T215D Y181C
DF013_RC B T215S
DF016 B G73S
DF021 B M41L, L210W, T215D L24I, M46L, V82A
SE RJ005_RC B K103N
RJ018 B D67G
RJ019 B D67N
RJ024_RC B V75M, F77L P225H
RJ036_RC B M41L, L210W, T215S Y188L
RJ052_RC B K101E, K103N, G190A
S POA_016 C M41L, L210W K101E, V106M, G190A
POA_023 C D67N
POA_025 CRF 31_BC L76V
POA_052 C G73S
POA_053 B M46I
POA_054 CRF 31_BC K103N
ST STOS_005 BD K103N
STOS_026 BF T69D
STOS_027 BF T69D
STOS_047 BF K103N I54T
STOS_683 F Y181I
STOS_902 B K103N
ST623 BF M41L, M184V, L210W, T215Y Y181I V32I, M46I, I47V, F53L, I85V
ST624 B M41L, D67N, K70R, L74I, M184V, T215F, K219Q K103N, Y188L
ITA ITA_018 C K65R
ITA_107 C M184I G73S
NNorth, NENortheast, MWMidwest, SESoutheast, SSouth, STSantos, ITAItajaı´.
de Moraes Soares CMP et al. Journal of the International AIDS Society 2014, 17:19042
http://www.jiasociety.org/index.php/jias/article/view/19042 | http://dx.doi.org/10.7448/IAS.17.1.19042
4
prevalences of subtype C towards the South and subtypes F
and BF towards the North. This study did not reveal differ-
ential TDR prevalences according to subtype, as previously
suggested. For instance, among recently diagnosed indivi-
duals in the South of Brazil, a higher prevalence of TDR among
individuals with subtype B than among individuals with
subtype C has been reported (Porto Alegre) [47]. As subtypes
other than B tend to fix and expand in the Western world,
perhaps more attention should be given to antiretroviral
resistance vis-a`-vis non-B subtypes. One study analysing
phenotypic resistance in a limited number of samples from
antiretroviral-naı¨ve individuals in Brazil revealed that geno-
typic correlates of subtype C resistance might not yet be
clearly defined [48]. Along a similar line of reasoning, certain
phenotypes of natural resistance to PIs might be encountered
in subtype F strains [49].
We recognize that the sampling technique used herein
might omit important information about TDR in a country of
continental size such as Brazil. However, we believe that the
results presented here justify checking TDR prior to starting
ART in Brazil, even if the samples are collected long after the
HIV transmission event, given that almost one-third of patients
harboured multi-class drug-resistant HIV genotypes. Further-
more, the use of DBS for antiretroviral resistance monitoring
was efficacious and might be cost-effective, especially in
settings in which resources are limited and when samples
need to be collected in remote regions for later processing in a
central laboratory. However, a portion of the samples (9.3%)
failed to provide reliable results using this strategy.
Authors’ affiliations
1Infectious Diseases Unit, Federal University of Sa˜o Paulo (UNIFESP), Sa˜o Paulo,
Brazil; 2Virology Research Laboratory, Federal University of Bahia, Salvador,
Brazil; 3Federal District Hospital Foundation, Brası´lia, Brazil; 4Molecular Biology
Laboratory, Lusı´ada University, Santos, SP, Brazil; 5Municipality of Itajaı´, Itajaı´,
Brazil; 6Municipality of Porto Alegre, Porto Alegre, Brazil; 7Infection Disease
Division, State University of Amazonas, Manaus, Brazil
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
CS performed the lab work; TV organized the samples transfer, samples collec-
tion, training for samples collection in DBS, and recruited patients from Rio
de Janeiro; CB recruited patients from Salvador; JB recruited patients from
Brasilia; GG and CC recruited patients from Itajai; MC recruited patients
from Santos; TS recruited patients from Porto Alegre; FP recruited samples
from Manaus; MC performed phylogenetic analysis; LJ data analysis; SK lab
work and data analysis; MS, data analysis and manuscript preparation; RD
design the study, data analysis and manuscript preparation.
Acknowledgements
This project has been funded in part with funds from Abbott Brazil, FAPESP
(2007/54923-1), CNPq (479957/2010-0) and PNPD/CAPES (2496/08). The
authors thank Jean Paulo Lopes Zukurov, MSc, for sequence phylogenetic
analyses, and Luiz Henrique Gagliani, PhD, for organizing biological material
from the city of Santos.
Figure 1. Map of Brazil depicting the different regions and cities in which the survey was conducted and the HIV-1 subtype prevalences.
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